The developing role of theranostics in NETs

Affiliations

¹ Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA. Electronic address: robert.ramirez@vumc.org.
² Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.

Comment

Robert A Ramirez et al. Lancet. 2024.

. 2024 Jun 29;403(10446):2759-2761.

doi: 10.1016/S0140-6736(24)00851-1. Epub 2024 Jun 5.

¹ Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA. Electronic address: robert.ramirez@vumc.org.
² Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.

No abstract available

Conflict of interest statement

We declare no competing interests.

[¹⁷⁷Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Singh S, et al. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. Lancet. 2024. PMID: 38851203 Clinical Trial.